South Africa’s health regulator asked the government to lift the pause on administering Johnson & Johnson’s Covid-19 vaccine provided certain conditions are met. “These conditions include, but are not limited to, strengthened screening and monitoring of participants who are at high risk of a blood clotting disorder,” the South African Health Products Regulatory Authority said in a statement. Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process. You will be redirected to a checkout page.
To view all features and options, click here. A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership. South Africa halted J&J vaccines after health agencies on Tuesday called for their suspension in the US. The J&J shot is a key element to South Africa’s vaccination plan and has already been used to inoculate health workers, with no reported adverse effects. Drug maker Aspen Pharmacare Holdings. will manufacture the J&J vaccine in South Africa for wider use. The government has been slow to rollout its vaccination program, and only 292 623 health-care workers had been inoculated with the J&J doses as of April 17. South Africa, which is the worst-affected country by the coronavirus pandemic on the continent, lags behind emerging market peers in vaccinations. © 2021 Bloomberg